Clinical Trial Site
Houston, Texas, United States
587 recruiting
Showing 1–20 of 40 trials
Recruiting
Phase 1
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Metastatic Hepatocellular CarcinomaAdvanced Hepatocellular Carcinoma
Alnylam Pharmaceuticals158 enrolled23 locationsNCT06600321
Recruiting
Phase 3
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-Negative Breast Carcinoma+2 more
Olema Pharmaceuticals, Inc.1,000 enrolled150 locationsNCT07085767
Recruiting
Phase 1
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
Early-Onset Alzheimer Disease
Alnylam Pharmaceuticals60 enrolled8 locationsNCT05231785
Recruiting
Phase 1
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
Alzheimer s Disease
Alnylam Pharmaceuticals50 enrolled13 locationsNCT07214727
Recruiting
Phase 1
A Study to Evaluate ALN-4285 in Adult Healthy Volunteers
Healthy Volunteers
Alnylam Pharmaceuticals76 enrolled1 locationNCT07295717
Recruiting
Phase 1
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
Huntington’s Disease
Alnylam Pharmaceuticals66 enrolled19 locationsNCT06585449
Recruiting
Phase 3
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals1,250 enrolled233 locationsNCT07052903
Recruiting
Phase 1Phase 2
A Study to Evaluate ALN-2232 in Participants With Obesity
Obesity
Alnylam Pharmaceuticals156 enrolled1 locationNCT07463846
Recruiting
Phase 1
A Study to Evaluate ALN-4915 in Adult Healthy Volunteers
Healthy Volunteers
Alnylam Pharmaceuticals44 enrolled1 locationNCT07535606
Recruiting
Phase 3
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Hereditary Transthyretin-Mediated Amyloidosis With PolyneuropathyhATTR-PN
Alnylam Pharmaceuticals125 enrolled29 locationsNCT07223203
Recruiting
Phase 2
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
Alnylam Pharmaceuticals200 enrolled57 locationsNCT06393712
Recruiting
Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
HypertensionHigh Risk Cardiovascular DiseaseHigh Cardiovascular Risk
Alnylam Pharmaceuticals11,000 enrolled856 locationsNCT07181109
Recruiting
Phase 1Phase 2
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Hereditary hemorrhagic telangiectasia
Alnylam Pharmaceuticals120 enrolled16 locationsNCT06659640
Recruiting
Phase 2
A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
Hypertension
Alnylam Pharmaceuticals93 enrolled3 locationsNCT07553442
Recruiting
Phase 2
A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus (T2DM)
Alnylam Pharmaceuticals40 enrolled1 locationNCT07465224
Recruiting
Phase 1Phase 2
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
Type 2 Diabetes Mellitus (T2DM)Obese or Overweight Healthy Volunteers
Alnylam Pharmaceuticals144 enrolled22 locationsNCT06845202
Recruiting
Phase 2
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
Angelman Syndrome
Ultragenyx Pharmaceutical Inc60 enrolled21 locationsNCT07157254
Recruiting
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
PolyneuropathyHereditary Transthyretin-mediated (hATTR) Amyloidosis
Alnylam Pharmaceuticals10 enrolled7 locationsNCT05040373
Recruiting
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Transthyretin-Mediated AmyloidosisATTR Amyloidosis
Alnylam Pharmaceuticals1,500 enrolled40 locationsNCT04561518
Recruiting
Phase 3
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Acute Myeloid Leukemias
Syndax Pharmaceuticals468 enrolled24 locationsNCT07211958